In this interview we discuss humanistic medicine and some of the skills that physicians need in order to have open communication with their cancer patients, which can improve the quality of cancer care.
Value in its essence is preference or outcome divided by cost, or described in terms of a mathematical equation, value = outcome (preference)/cost. It follows, then, that value is increased by holding outcome constant and reducing cost, or by improving outcome while holding cost constant.
Ultimately, meaningful value assessment is going to require unbiased comparisons between competing strategies. Decision models are extremely useful in this regard and can provide important insight into cost-effectiveness evaluations.
Sexual health is an important aspect of human life, and cancer does not (and should not) change that. Data suggest that issues related to sexual function are quite common among women treated for cancer. However, clinicians often spend little to no time on the topic.
PARP inhibitors are an active, novel, and exciting class of anticancer agents. They have shown clear patient benefit in gBRCA, HR-deficient, and other ovarian cancers.
A 48-year-old Caucasian woman presented with a palpable right breast mass. Physical examination confirmed a lump on the upper outer quadrant of her right breast. On PET/CT scan there was an incidental finding of increased metabolic activity in the left lateral breast.
How Can We Effectively Address the Medical and Psychological Concerns of Survivors of Pelvic Malignancies?
Sexual and urinary morbidities resulting from treatment of pelvic malignancies are common. Awareness of these complications is critical in order to properly counsel patients regarding potential side effects and to facilitate prompt diagnosis and management.
Molecular Testing to Optimize and Personalize Decision Making in the Management of Colorectal Cancer
Recent improvements in our understanding of the biology of colorectal cancer have led to the identification of several important prognostic and predictive markers of disease-associated risk and treatment response for the individual patient.